The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If ...

Overall, Snap trades at a valuation that remains questionable given its history of dilution and heavy reliance on noncash compensation. But the emergence of fast-growing subscription revenue, ...

While these two risks don't necessarily call for the sale of the stock, they do mean that investors should think carefully ...

Berkshire Hathaway recently filed its second-quarter 13F form, revealing its stock holdings at the end of June.

These cruise lines are performing excellently, as the post-pandemic travel surge shows no signs of letting up. But which is the better buy?